Gene:
MAP2K1
mitogen-activated protein kinase kinase 1

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  PRKMK1
Alternate Symbols:  MAPKK1; MEK1
PharmGKB Accession Id: PA30584

Details

Cytogenetic Location: chr15 : q22.1 - q22.33
GP mRNA Boundary: chr15 : 66679182 - 66783882
GP Gene Boundary: chr15 : 66669182 - 66786882
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Sorafenib Pharmacodynamics
    Mechanism of action of sorafenib
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

Curated Information ?

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
antipsychotics

Curated Information ?

Publications related to MAP2K1: 13

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature genetics. 2015. Shain A Hunter, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Johnson Douglas B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012. Sharma Anant, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012. McCubrey James A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Molecular cancer therapeutics. 2012. Greger James G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010. Ramakrishnan V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics. 2008. Mill Jonathan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nature genetics. 2007. Razzaque M Abdur, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007. Tissing Wim J E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (New York, N.Y.). 2006. Rodriguez-Viciana Pablo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of Raf in vascular protection from distinct apoptotic stimuli. Science (New York, N.Y.). 2003. Alavi Alireza, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. The Journal of clinical investigation. 2003. Tiede Imke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al. PubMed

LinkOuts

NCBI Gene:
5604
OMIM:
115150
176872
UCSC Genome Browser:
NM_002755
RefSeq RNA:
NM_002755
RefSeq Protein:
NP_002746
RefSeq DNA:
NG_008305
NT_010194
UniProtKB:
A4QPA9_HUMAN (A4QPA9)
MP2K1_HUMAN (Q02750)
Ensembl:
ENSG00000169032
GenAtlas:
MAP2K1
GeneCard:
MAP2K1
MutDB:
MAP2K1
ALFRED:
LO006499C
HuGE:
MAP2K1
Comparative Toxicogenomics Database:
5604
ModBase:
Q02750
HumanCyc Gene:
HS09869
HGNC:
6840

Common Searches